

Christoph U Correll

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/10760953/publications.pdf>

Version: 2024-02-01

261
papers

31,018
citations

4388

86
h-index

5120

166
g-index

264
all docs

264
docs citations

264
times ranked

20478
citing authors

#	ARTICLE	IF	CITATIONS
1	Safety and effectiveness of lurasidone in adolescents with schizophrenia: results of a 2-year, open-label extension study. <i>CNS Spectrums</i> , 2022, 27, 118-128.	1.2	11
2	The collaborative outcomes study on health and functioning during infection times in adults (COH-FIT-Adults): Design and methods of an international online survey targeting physical and mental health effects of the COVID-19 pandemic. <i>Journal of Affective Disorders</i> , 2022, 299, 393-407.	4.1	22
3	Antipsychotics Use Is Associated With Greater Adherence to Cardiometabolic Medications in Patients With Schizophrenia: Results From a Nationwide, Within-subject Design Study. <i>Schizophrenia Bulletin</i> , 2022, 48, 166-175.	4.3	26
4	Outcomes associated with different vaccines in individuals with bipolar disorder and impact on the current COVID-19 pandemic- a systematic review. <i>European Neuropsychopharmacology</i> , 2022, 54, 90-99.	0.7	5
5	Long-term efficacy and safety of once-monthly Risperidone ISM [®] in the treatment of schizophrenia: Results from a 12-month open-label extension study. <i>Schizophrenia Research</i> , 2022, 239, 83-91.	2.0	5
6	The post COVID-19 healthcare landscape and the use of long-acting injectable antipsychotics for individuals with schizophrenia and bipolar I disorder: the importance of an integrated collaborative-care approach. <i>BMC Psychiatry</i> , 2022, 22, 32.	2.6	11
7	Long-term safety and effectiveness of open-label lurasidone in antipsychotic-naïve versus previously treated adolescents with Schizophrenia: A post-hoc analysis. <i>Schizophrenia Research</i> , 2022, 240, 205-213.	2.0	3
8	Treatment Approaches for First Episode and Early-Phase Schizophrenia in Adolescents and Young Adults: A Delphi Consensus Report from Europe. <i>Neuropsychiatric Disease and Treatment</i> , 2022, Volume 18, 201-219.	2.2	3
9	Systematic literature review of schizophrenia clinical practice guidelines on acute and maintenance management with antipsychotics. <i>NPJ Schizophrenia</i> , 2022, 8, 5.	3.6	48
10	Psychological and Psychopharmacological Interventions in Psychocardiology. <i>Frontiers in Psychiatry</i> , 2022, 13, 831359.	2.6	19
11	Amisulpride and olanzapine combination treatment versus each monotherapy in acutely ill patients with schizophrenia in Germany (COMBINE): a double-blind randomised controlled trial. <i>Lancet Psychiatry</i> , 2022, 9, 291-306.	7.4	6
12	Half a century of research on antipsychotics and schizophrenia: A scientometric study of hotspots, nodes, bursts, and trends. <i>Neuroscience and Biobehavioral Reviews</i> , 2022, 136, 104608.	6.1	67
13	An International Adult Guideline for Making Clozapine Titration Safer by Using Six Ancestry-Based Personalized Dosing Titrations, CRP, and Clozapine Levels. <i>Pharmacopsychiatry</i> , 2022, 55, 73-86.	3.3	107
14	Short-term efficacy and safety of lurasidone versus placebo in antipsychotic-naïve versus previously treated adolescents with an acute exacerbation of schizophrenia. <i>European Psychiatry</i> , 2022, 65, 1-35.	0.2	4
15	Temporal trends in associations between severe mental illness and risk of cardiovascular disease: A systematic review and meta-analysis. <i>PLoS Medicine</i> , 2022, 19, e1003960.	8.4	43
16	Associations between mental and physical conditions in children and adolescents: An umbrella review. <i>Neuroscience and Biobehavioral Reviews</i> , 2022, 137, 104662.	6.1	30
17	Mortality in people with schizophrenia: a systematic review and meta-analysis of relative risk and aggravating or attenuating factors. <i>World Psychiatry</i> , 2022, 21, 248-271.	10.4	156
18	Oral and long-acting antipsychotics for relapse prevention in schizophrenia spectrum disorders: a network meta-analysis of 92 randomized trials including 22,645 participants. <i>World Psychiatry</i> , 2022, 21, 295-307.	10.4	44

#	ARTICLE	IF	CITATIONS
19	The transition from adolescence to adulthood in patients with schizophrenia: Challenges, opportunities and recommendations. <i>European Neuropsychopharmacology</i> , 2022, 59, 45-55.	0.7	7
20	Drug-drug interactions involving antipsychotics and antihypertensives. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2022, 18, 285-298.	3.3	4
21	Brain stimulation and other biological non-pharmacological interventions in mental disorders: An umbrella review. <i>Neuroscience and Biobehavioral Reviews</i> , 2022, 139, 104743.	6.1	41
22	Outcomes During and After Early Intervention Services for First-Episode Psychosis: Results Over 5 Years From the RAISE-ETP Site-Randomized Trial. <i>Schizophrenia Bulletin</i> , 2022, 48, 1021-1031.	4.3	7
23	Clozapine's multiple cellular mechanisms: What do we know after more than fifty years? A systematic review and critical assessment of translational mechanisms relevant for innovative strategies in treatment-resistant schizophrenia. , 2022, 236, 108236.		19
24	The report of the joint WPA/CINP workgroup on the use and usefulness of antipsychotic medication in the treatment of schizophrenia. <i>CNS Spectrums</i> , 2021, 26, 562-586.	1.2	13
25	Oxidative stress parameters and antioxidants in patients with bipolar disorder: Results from a meta-analysis comparing patients, including stratification by polarity and euthymic status, with healthy controls. <i>Bipolar Disorders</i> , 2021, 23, 117-129.	1.9	53
26	Mortality After the First Diagnosis of Schizophrenia-Spectrum Disorders: A Population-based Retrospective Cohort Study. <i>Schizophrenia Bulletin</i> , 2021, 47, 864-874.	4.3	21
27	Does Switching Antipsychotics Ameliorate Weight Gain in Patients With Severe Mental Illness? A Systematic Review and Meta-analysis. <i>Schizophrenia Bulletin</i> , 2021, 47, 948-958.	4.3	26
28	Safety and tolerability of lumateperone 42Âmg: An open-label antipsychotic switch study in outpatients with stable schizophrenia. <i>Schizophrenia Research</i> , 2021, 228, 198-205.	2.0	16
29	How can we improve antidepressant adherence in the management of depression? A targeted review and 10 clinical recommendations. <i>Revista Brasileira De Psiquiatria</i> , 2021, 43, 189-202.	1.7	32
30	Association of Low-Dose Quetiapine and Diabetes. <i>JAMA Network Open</i> , 2021, 4, e213209.	5.9	14
31	Development of a Symptom-Focused Model to Guide the Prescribing of Antipsychotics in Children and Adolescents: Results of the First Phase of the Safer and Targeted Use of Antipsychotics (SUAY) Clinical Trial. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , 2021, , .	0.5	6
32	Preventive psychiatry: a blueprint for improving the mental health of young people. <i>World Psychiatry</i> , 2021, 20, 200-221.	10.4	183
33	Socio-economic position as a moderator of cardiometabolic outcomes in patients receiving psychotropic treatment associated with weight gain: results from a prospective 12-month inception cohort study and a large population-based cohort. <i>Translational Psychiatry</i> , 2021, 11, 360.	4.8	8
34	Dietary Consumption Among Youth with Antipsychotic-Induced Weight Gain and Changes Following Healthy Lifestyle Education. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2021, 31, 364-375.	1.3	4
35	Risk and protective factors for mental disorders beyond genetics: an evidence-based atlas. <i>World Psychiatry</i> , 2021, 20, 417-436.	10.4	127
36	The Impact of Pharmacological and Non-Pharmacological Interventions to Improve Physical Health Outcomes in People With Schizophrenia: A Meta-Review of Meta-Analyses of Randomized Controlled Trials. <i>Focus (American Psychiatric Publishing)</i> , 2021, 19, 116-128.	0.8	7

#	ARTICLE	IF	CITATIONS
37	What are the physical and mental health implications of duration of untreated psychosis?. <i>European Psychiatry</i> , 2021, 64, e46.	0.2	3
38	Longitudinal Course of Depressive, Anxiety, and Posttraumatic Stress Disorder Symptoms After Heart Surgery: A Meta-Analysis of 94 Studies. <i>Psychosomatic Medicine</i> , 2021, 83, 85-93.	2.0	15
39	Controversies Surrounding the Use of Long-Acting Injectable Antipsychotic Medications for the Treatment of Patients with Schizophrenia. <i>CNS Drugs</i> , 2021, 35, 1189-1205.	5.9	32
40	Safety and effectiveness of ulotaront (SEP-363856) in schizophrenia: results of a 6-month, open-label extension study. <i>NPJ Schizophrenia</i> , 2021, 7, 63.	3.6	39
41	Network analysis of the relationship between depressive symptoms, demographics, nutrition, quality of life and medical condition factors in the Osteoarthritis Initiative database cohort of elderly North-American adults with or at risk for osteoarthritis. <i>Epidemiology and Psychiatric Sciences</i> , 2020, 29, e14.	3.9	20
42	Impact of age and CYP2D6 genetics on exposure of aripiprazole and dehydroaripiprazole in patients using long-acting injectable versus oral formulation: relevance of poor and intermediate metabolizer status. <i>European Journal of Clinical Pharmacology</i> , 2020, 76, 41-49.	1.9	13
43	A randomized double-blind controlled trial to assess the benefits of amisulpride and olanzapine combination treatment versus each monotherapy in acutely ill schizophrenia patients (COMBINE): methods and design. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2020, 270, 83-94.	3.2	4
44	20-year follow-up study of physical morbidity and mortality in relationship to antipsychotic treatment in a nationwide cohort of 62,250 patients with schizophrenia (FIN20). <i>World Psychiatry</i> , 2020, 19, 61-68.	10.4	232
45	The neurobiology of treatment-resistant schizophrenia: paths to antipsychotic resistance and a roadmap for future research. <i>NPJ Schizophrenia</i> , 2020, 6, 1.	3.6	193
46	Efficacy and Safety of Lumateperone for Treatment of Schizophrenia. <i>JAMA Psychiatry</i> , 2020, 77, 349.	11.0	226
47	Metformin addition vs. antipsychotic switch vs. continued antipsychotic treatment plus healthy lifestyle education in overweight or obese youth with severe mental illness: results from the IMPACT trial. <i>World Psychiatry</i> , 2020, 19, 69-80.	10.4	68
48	Predictors of psychosis breakthrough during 24 months of long-acting antipsychotic maintenance treatment in first episode schizophrenia. <i>Schizophrenia Research</i> , 2020, 225, 55-62.	2.0	23
49	Disparities in cancer screening in people with mental illness across the world versus the general population: prevalence and comparative meta-analysis including 4717839 people. <i>Lancet Psychiatry</i> , 2020, 7, 52-63.	7.4	109
50	Leptin Serum Levels are Associated With GLP-1 Receptor Agonist-Mediated Effects on Glucose Metabolism in Clozapine- or Olanzapine-Treated, Prediabetic, Schizophrenia Patients. <i>Schizophrenia Bulletin Open</i> , 2020, 1, .	1.7	3
51	Medical management of eating disorders: an update. <i>Current Opinion in Psychiatry</i> , 2020, 33, 542-553.	6.3	31
52	Psychosis relapse during treatment with long-acting injectable antipsychotics in individuals with schizophrenia-spectrum disorders: an individual participant data meta-analysis. <i>Lancet Psychiatry</i> , 2020, 7, 749-761.	7.4	66
53	How mental health care should change as a consequence of the COVID-19 pandemic. <i>Lancet Psychiatry</i> , 2020, 7, 813-824.	7.4	1,101
54	Safety of psychotropic medications in people with COVID-19: evidence review and practical recommendations. <i>BMC Medicine</i> , 2020, 18, 215.	5.5	52

#	ARTICLE	IF	CITATIONS
55	Universal and selective interventions to promote good mental health in young people: Systematic review and meta-analysis. <i>European Neuropsychopharmacology</i> , 2020, 41, 28-39.	0.7	56
56	Pharmacological Management of Glucose Dysregulation in Patients Treated with Second-Generation Antipsychotics. <i>Drugs</i> , 2020, 80, 1763-1781.	10.9	39
57	Consensus statement on the use of clozapine during the COVID-19 pandemic. <i>Journal of Psychiatry and Neuroscience</i> , 2020, 45, 222-223.	2.4	102
58	Clozapine Combination and Augmentation Strategies in Patients With Schizophrenia – Recommendations From an International Expert Survey Among the Treatment Response and Resistance in Psychosis (TRRIP) Working Group. <i>Schizophrenia Bulletin</i> , 2020, 46, 1459-1470.	4.3	58
59	Clinical validation of the self-reported Glasgow Antipsychotic Side-effect Scale using the clinician-rated UKU side-effect scale as gold standard reference. <i>Journal of Psychopharmacology</i> , 2020, 34, 820-828.	4.0	12
60	A symptom combination predicting treatment-resistant schizophrenia – A strategy for real-world clinical practice. <i>Schizophrenia Research</i> , 2020, 218, 195-200.	2.0	16
61	Frequency and Correlates of Acute Dystonic Reactions After Antipsychotic Initiation in 441 Children and Adolescents. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2020, 30, 366-375.	1.3	3
62	Safety of Psychotropic Medications in People With COVID-19: Evidence Review and Practical Recommendations. <i>Focus (American Psychiatric Publishing)</i> , 2020, 18, 466-481.	0.8	6
63	The Neurobiology of Treatment-Resistant Schizophrenia: Paths to Antipsychotic Resistance and A Roadmap for Future Research. <i>Focus (American Psychiatric Publishing)</i> , 2020, 18, 456-465.	0.8	8
64	Diagnostic stability in children and adolescents with bipolar disorder, a nationwide register-based study. <i>International Journal of Bipolar Disorders</i> , 2020, 8, 14.	2.2	3
65	Rejoinder to rejoinder to commentary. <i>Psychological Medicine</i> , 2020, 50, 2812-2813.	4.5	0
66	Cariprazine in the management of negative symptoms of schizophrenia: state-of-the-art and future perspectives. <i>Future Neurology</i> , 2020, 15, .	0.5	7
67	Association With Hospitalization and All-Cause Discontinuation Among Patients With Schizophrenia on Clozapine vs Other Oral Second-Generation Antipsychotics. <i>JAMA Psychiatry</i> , 2019, 76, 1052.	11.0	243
68	The Lancet Psychiatry Commission: a blueprint for protecting physical health in people with mental illness. <i>Lancet Psychiatry</i> , 2019, 6, 675-712.	7.4	815
69	Patient characteristics, burden and pharmacotherapy of treatment-resistant schizophrenia: results from a survey of 204 US psychiatrists. <i>BMC Psychiatry</i> , 2019, 19, 362.	2.6	35
70	Keeping up with the therapeutic advances in schizophrenia: a review of novel and emerging pharmacological entities. <i>CNS Spectrums</i> , 2019, 24, 38-69.	1.2	87
71	An open-label randomised comparison of aripiprazole, olanzapine and risperidone for the acute treatment of first-episode schizophrenia: Eight-week outcomes. <i>Journal of Psychopharmacology</i> , 2019, 33, 1227-1236.	4.0	24
72	Lifestyle Interventions for Weight Management in People with Serious Mental Illness: A Systematic Review with Meta-Analysis, Trial Sequential Analysis, and Meta-Regression Analysis Exploring the Mediators and Moderators of Treatment Effects. <i>Psychotherapy and Psychosomatics</i> , 2019, 88, 350-362.	8.8	60

#	ARTICLE	IF	CITATIONS
73	Association of Antidepressant Use With Adverse Health Outcomes. <i>JAMA Psychiatry</i> , 2019, 76, 1241.	11.0	143
74	Abnormal involuntary movement scale in tardive dyskinesia: Minimal clinically important difference. <i>Movement Disorders</i> , 2019, 34, 1203-1209.	3.9	18
75	Cardiometabolic Adverse Effects and Its Predictors in Children and Adolescents With First-Episode Psychosis During Treatment With Quetiapine-Extended Release Versus Aripiprazole: 12-Week Results From the Tolerance and Effect of Antipsychotics in Children and Adolescents With Psychosis (TEA) Trial. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , 2019, 58, 1062-1078.	0.5	16
76	Trends in utilization and dosing of antipsychotic drugs in Scandinavia: Comparison of 2006 and 2016. <i>British Journal of Clinical Pharmacology</i> , 2019, 85, 1598-1606.	2.4	38
77	Association of Antipsychotic Polypharmacy vs Monotherapy With Psychiatric Rehospitalization Among Adults With Schizophrenia. <i>JAMA Psychiatry</i> , 2019, 76, 499.	11.0	191
78	<p>Exploration of Treatment-Resistant Schizophrenia Subtypes Based on a Survey of 204 US Psychiatrists</p>. <i>Neuropsychiatric Disease and Treatment</i> , 2019, Volume 15, 3461-3473.	2.2	10
79	Clinical Guidance on the Identification and Management of Treatment-Resistant Schizophrenia. <i>Journal of Clinical Psychiatry</i> , 2019, 80, .	2.2	157
80	Long-Acting Injections in Schizophrenia: a 3-Year Update on Randomized Controlled Trials Published January 2016â€“March 2019. <i>Current Psychiatry Reports</i> , 2019, 21, 124.	4.5	16
81	Glucagonâ€like peptideâ€1 receptor agonists for antipsychoticâ€associated cardioâ€metabolic risk factors: A systematic review and individual participant data metaâ€analysis. <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 293-302.	4.4	69
82	The impact of pharmacological and nonâ€pharmacological interventions to improve physical health outcomes in people with schizophrenia: a metaâ€review of metaâ€analyses of randomized controlled trials. <i>World Psychiatry</i> , 2019, 18, 53-66.	10.4	153
83	High prevalence of prediabetes and metabolic abnormalities in overweight or obese schizophrenia patients treated with clozapine or olanzapine. <i>CNS Spectrums</i> , 2019, 24, 441-452.	1.2	15
84	Practical considerations for managing breakthrough psychosis and symptomatic worsening in patients with schizophrenia on long-acting injectable antipsychotics. <i>CNS Spectrums</i> , 2019, 24, 354-370.	1.2	17
85	Clozapine and Long-Term Mortality Risk in Patients With Schizophrenia: A Systematic Review and Meta-analysis of Studies Lasting 1.1â€“12.5 Years. <i>Schizophrenia Bulletin</i> , 2019, 45, 315-329.	4.3	141
86	Clinical risk factors for the development of tardive dyskinesia. <i>Journal of the Neurological Sciences</i> , 2018, 389, 21-27.	0.6	89
87	National Patterns of Commonly Prescribed Psychotropic Medications to Young People. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2018, 28, 158-165.	1.3	43
88	The pharmacological management of metabolic syndrome. <i>Expert Review of Clinical Pharmacology</i> , 2018, 11, 397-410.	3.1	80
89	Comparison of Early Intervention Services vs Treatment as Usual for Early-Phase Psychosis. <i>JAMA Psychiatry</i> , 2018, 75, 555.	11.0	516
90	The Validity and Sensitivity of PANSS-6 in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Study. <i>Schizophrenia Bulletin</i> , 2018, 44, 453-462.	4.3	25

#	ARTICLE	IF	CITATIONS
91	Psychopharmacological Treatment in the RAISE-ETP Study: Outcomes of a Manual and Computer Decision Support System Based Intervention. <i>American Journal of Psychiatry</i> , 2018, 175, 169-179.	7.2	46
92	A randomized, double-blind, placebo-controlled proof of concept study to evaluate samidorphan in the prevention of olanzapine-induced weight gain in healthy volunteers. <i>Schizophrenia Research</i> , 2018, 195, 245-251.	2.0	42
93	Change and dispersion of QT interval during treatment with quetiapine extended release versus aripiprazole in children and adolescents with first-episode psychosis: results from the TEA trial. <i>Psychopharmacology</i> , 2018, 235, 681-693.	3.1	7
94	Comorbidity of chronic somatic diseases in patients with psychotic disorders and their influence on 4-year outcomes of integrated care treatment (ACCESS II study). <i>Schizophrenia Research</i> , 2018, 193, 377-383.	2.0	22
95	EPA guidance on physical activity as a treatment for severe mental illness: a meta-review of the evidence and Position Statement from the European Psychiatric Association (EPA), supported by the International Organization of Physical Therapists in Mental Health (IOPTMH). <i>European Psychiatry</i> , 2018, 54, 124-144.	0.2	377
96	Sex and body weight are major determinants of venlafaxine pharmacokinetics. <i>International Clinical Psychopharmacology</i> , 2018, 33, 322-329.	1.7	12
97	The acute efficacy of antipsychotics in schizophrenia: a review of recent meta-analyses. <i>Therapeutic Advances in Psychopharmacology</i> , 2018, 8, 303-318.	2.7	129
98	Tardive dyskinesia risk with first- and second-generation antipsychotics in comparative randomized controlled trials: a meta-analysis. <i>World Psychiatry</i> , 2018, 17, 330-340.	10.4	117
99	Treatment of tardive dyskinesia with VMAT-2 inhibitors: a systematic review and meta-analysis of randomized controlled trials. <i>Drug Design, Development and Therapy</i> , 2018, Volume 12, 1215-1238.	4.3	51
100	Age Impacts Olanzapine Exposure Differently During Use of Oral Versus Long-Acting Injectable Formulations. <i>Journal of Clinical Psychopharmacology</i> , 2018, 38, 570-576.	1.4	17
101	What is the risk-benefit ratio of long-term antipsychotic treatment in people with schizophrenia?. <i>World Psychiatry</i> , 2018, 17, 149-160.	10.4	188
102	ECT augmentation of clozapine for clozapine-resistant schizophrenia: A meta-analysis of randomized controlled trials. <i>Journal of Psychiatric Research</i> , 2018, 105, 23-32.	3.1	71
103	Impact of comprehensive treatment for first episode psychosis on substance use outcomes: A randomized controlled trial. <i>Psychiatry Research</i> , 2018, 268, 303-311.	3.3	44
104	Clozapine and long-acting injectable antipsychotics reduce hospitalisation and treatment failure risk in patients with schizophrenia. <i>Evidence-Based Mental Health</i> , 2018, 21, e11-e11.	4.5	0
105	Initiating/maintaining long-acting injectable antipsychotics in schizophrenia/schizoaffective or bipolar disorder – expert consensus survey part 2. <i>Neuropsychiatric Disease and Treatment</i> , 2018, Volume 14, 1475-1492.	2.2	21
106	Antipsychotic Medication Treatment Patterns in Adult Depression. <i>Journal of Clinical Psychiatry</i> , 2018, 79, 55-61.	2.2	13
107	Antipsychotic augmentation vs. monotherapy in schizophrenia: systematic review, meta-analysis and meta-regression analysis. <i>World Psychiatry</i> , 2017, 16, 77-89.	10.4	156
108	Reduced all-cause mortality with antipsychotics and antidepressants compared to increased all-cause mortality with benzodiazepines in patients with schizophrenia observed in naturalistic treatment settings. <i>Evidence-Based Mental Health</i> , 2017, 20, e6-e6.	4.5	5

#	ARTICLE	IF	CITATIONS
109	Impairment in Social Functioning differentiates youth meeting Ultra-High Risk for psychosis criteria from other mental health help-seekers: A validation of the Italian version of the Global Functioning: Social and Global Functioning: Role scales. <i>Psychiatry Research</i> , 2017, 253, 296-302.	3.3	13
110	Prevalence, incidence and mortality from cardiovascular disease in patients with pooled and specific severe mental illness: a large-scale meta-analysis of 3,211,768 patients and 113,383,368 controls. <i>World Psychiatry</i> , 2017, 16, 163-180.	10.4	1,082
111	A Severity-Based Clinical Staging Model for the Psychosis Prodrome: Longitudinal Findings From the New York Recognition and Prevention Program. <i>Schizophrenia Bulletin</i> , 2017, 43, 64-74.	4.3	54
112	Efficacy of 42 Pharmacologic Cotreatment Strategies Added to Antipsychotic Monotherapy in Schizophrenia. <i>JAMA Psychiatry</i> , 2017, 74, 675.	11.0	153
113	Atypical antipsychotics: recent research findings and applications to clinical practice: Proceedings of a symposium presented at the 29th Annual European College of Neuropsychopharmacology Congress, 19 September 2016, Vienna, Austria. <i>Therapeutic Advances in Psychopharmacology</i> , 2017, 7, 1-14.	2.7	20
114	Cardiometabolic comorbidities, readmission, and costs in schizophrenia and bipolar disorder: a real-world analysis. <i>Annals of General Psychiatry</i> , 2017, 16, 9.	2.7	49
115	Psychological well-being and mental health recovery in the NIMH RAISE early treatment program. <i>Schizophrenia Research</i> , 2017, 185, 167-172.	2.0	29
116	Treatment-Resistant Schizophrenia: Treatment Response and Resistance in Psychosis (TRRIP) Working Group Consensus Guidelines on Diagnosis and Terminology. <i>American Journal of Psychiatry</i> , 2017, 174, 216-229.	7.2	685
117	Polypharmacy in Youth Treated With Antipsychotics: Do Antidepressants or Stimulants Add to the Risk for Type 2 Diabetes?. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , 2017, 56, 634-635.	0.5	4
118	Oral Aripiprazole as Maintenance Treatment in Adolescent Schizophrenia: Results From a 52-Week, Randomized, Placebo-Controlled Withdrawal Study. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , 2017, 56, 784-792.	0.5	21
119	A new class of VMAT-2 inhibitors for tardive dyskinesia. <i>Lancet Psychiatry</i> , 2017, 4, 574-575.	7.4	3
120	Safety, tolerability, and risks associated with first- and second-generation antipsychotics: a state-of-the-art clinical review. <i>Therapeutics and Clinical Risk Management</i> , 2017, Volume 13, 757-777.	2.0	286
121	The association between smoking prevalence and eating disorders: a systematic review and meta-analysis. <i>Addiction</i> , 2016, 111, 1914-1922.	3.3	65
122	Digital Parent Training for Children with Disruptive Behaviors: Systematic Review and Meta-Analysis of Randomized Trials. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2016, 26, 740-749.	1.3	88
123	Pharmacogenetic Associations of Antipsychotic Drug-Related Weight Gain: A Systematic Review and Meta-analysis. <i>Schizophrenia Bulletin</i> , 2016, 42, 1418-1437.	4.3	149
124	ITI-007 in the treatment of schizophrenia: from novel pharmacology to clinical outcomes. <i>Expert Review of Neurotherapeutics</i> , 2016, 16, 601-614.	2.8	40
125	Antipsychotic Use Trends in Youth With Autism Spectrum Disorder and/or Intellectual Disability: A Meta-Analysis. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , 2016, 55, 456-468.e4.	0.5	57
126	Diabetes mellitus in people with schizophrenia, bipolar disorder and major depressive disorder: a systematic review and large scale meta-analysis. <i>World Psychiatry</i> , 2016, 15, 166-174.	10.4	487

#	ARTICLE	IF	CITATIONS
127	Physical multimorbidity and psychosis: comprehensive cross sectional analysis including 242,952 people across 48 low- and middle-income countries. <i>BMC Medicine</i> , 2016, 14, 189.	5.5	119
128	Duration of attenuated positive and negative symptoms in individuals at clinical high risk: Associations with risk of conversion to psychosis and functional outcome. <i>Journal of Psychiatric Research</i> , 2016, 81, 95-101.	3.1	70
129	Activating and Tranquilizing Effects of First-Time Treatment with Aripiprazole, Olanzapine, Quetiapine, and Risperidone in Youth. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2016, 26, 458-470.	1.3	20
130	Self-Reported and Interviewer-Rated Oral Health in Patients With Schizophrenia, Bipolar Disorder, and Major Depressive Disorder. <i>Perspectives in Psychiatric Care</i> , 2016, 52, 4-11.	1.9	16
131	The Role of Clozapine in Treatment-Resistant Schizophrenia. <i>JAMA Psychiatry</i> , 2016, 73, 187.	11.0	72
132	Safety and tolerability of antipsychotic co-treatment in patients with schizophrenia: results from a systematic review and meta-analysis of randomized controlled trials. <i>Expert Opinion on Drug Safety</i> , 2016, 15, 591-612.	2.4	29
133	Attenuated psychotic and basic symptom characteristics in adolescents with ultra-high risk criteria for psychosis, other non-psychotic psychiatric disorders and early-onset psychosis. <i>European Child and Adolescent Psychiatry</i> , 2016, 25, 1091-1102.	4.7	26
134	Comprehensive Versus Usual Community Care for First-Episode Psychosis: 2-Year Outcomes From the NIMH RAISE Early Treatment Program. <i>American Journal of Psychiatry</i> , 2016, 173, 362-372.	7.2	601
135	Cardiovascular and cerebrovascular risk factors and events associated with second-generation antipsychotic compared to antidepressant use in a non-elderly adult sample: results from a claims-based inception cohort study. <i>World Psychiatry</i> , 2015, 14, 56-63.	10.4	82
136	Effects of antipsychotics, antidepressants and mood stabilizers on risk for physical diseases in people with schizophrenia, depression and bipolar disorder. <i>World Psychiatry</i> , 2015, 14, 119-136.	10.4	581
137	Schizophrenia. <i>Nature Reviews Disease Primers</i> , 2015, 1, 15067.	30.5	724
138	Decreased pain sensitivity among people with schizophrenia. <i>Pain</i> , 2015, 156, 2121-2131.	4.2	95
139	Psychosis Prevention: A Modified Clinical High Risk Perspective From the Recognition and Prevention (RAP) Program. <i>American Journal of Psychiatry</i> , 2015, 172, 986-994.	7.2	128
140	Early Improvement As a Predictor of Later Response to Antipsychotics in Schizophrenia: A Diagnostic Test Review. <i>American Journal of Psychiatry</i> , 2015, 172, 617-629.	7.2	150
141	Risk of metabolic syndrome and its components in people with schizophrenia and related psychotic disorders, bipolar disorder and major depressive disorder: a systematic review and meta-analysis. <i>World Psychiatry</i> , 2015, 14, 339-347.	10.4	858
142	Neuromotor Adverse Effects in 342 Youth During 12 Weeks of Naturalistic Treatment With 5 Second-Generation Antipsychotics. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , 2015, 54, 718-727.e3.	0.5	32
143	Unmet needs in paediatric psychopharmacology: Present scenario and future perspectives. <i>European Neuropsychopharmacology</i> , 2015, 25, 1513-1531.	0.7	56
144	Frequency and correlates of antipsychotic polypharmacy among patients with schizophrenia in Denmark: A nation-wide pharmacoepidemiological study. <i>European Neuropsychopharmacology</i> , 2015, 25, 1669-1676.	0.7	27

#	ARTICLE	IF	CITATIONS
145	Child and Adolescent Psychiatrists' Reported Monitoring Behaviors for Second-Generation Antipsychotics. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2015, 25, 351-361.	1.3	35
146	Antipsychotic polypharmacy in schizophrenia patients in China and its association with treatment satisfaction and quality of life: Findings of the third national survey on use of psychotropic medications in China. <i>Australian and New Zealand Journal of Psychiatry</i> , 2015, 49, 129-136.	2.3	40
147	Duration of Untreated Psychosis in Community Treatment Settings in the United States. <i>Psychiatric Services</i> , 2015, 66, 753-756.	2.0	100
148	Outcome of Youth with Early-Phase Schizophrenia-Spectrum Disorders and Psychosis Not Otherwise Specified Treated with Second-Generation Antipsychotics: 12 Week Results from a Prospective, Naturalistic Cohort Study. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2015, 25, 535-547.	1.3	8
149	A Randomized Comparison of Aripiprazole and Risperidone for the Acute Treatment of First-Episode Schizophrenia and Related Disorders: 3-Month Outcomes. <i>Schizophrenia Bulletin</i> , 2015, 41, 1227-1236.	4.3	100
150	Clozapine in schizophrenia and its association with treatment satisfaction and quality of life: Findings of the three national surveys on use of psychotropic medications in China (2002-2012). <i>Schizophrenia Research</i> , 2015, 168, 523-529.	2.0	17
151	Lack of cardinal symptoms of meningitis in a hospitalized patient with chronic schizophrenia: lessons to be learned. <i>General Hospital Psychiatry</i> , 2015, 37, 621.e3-621.e4.	2.4	2
152	Do antipsychotics increase diabetes risk in children and adolescents?. <i>Expert Opinion on Drug Safety</i> , 2015, 14, 219-241.	2.4	29
153	Corrected QT Changes During Antipsychotic Treatment of Children and Adolescents: A Systematic Review and Meta-Analysis of Clinical Trials. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , 2015, 54, 25-36.	0.5	62
154	Prescription Practices in the Treatment of First-Episode Schizophrenia Spectrum Disorders: Data From the National RAISE-ETP Study. <i>American Journal of Psychiatry</i> , 2015, 172, 237-248.	7.2	80
155	The RAISE Early Treatment Program for First-Episode Psychosis. <i>Journal of Clinical Psychiatry</i> , 2015, 76, 240-246.	2.2	121
156	Can an early weight management program (WMP) prevent olanzapine (OLZ)-induced disturbances in body weight, blood glucose and lipid metabolism? Twenty-four- and 48-week results from a 6-month randomized trial. <i>World Journal of Biological Psychiatry</i> , 2014, 15, 229-241.	2.6	18
157	Does a GLP-1 receptor agonist change glucose tolerance in patients treated with antipsychotic medications? Design of a randomised, double-blinded, placebo-controlled clinical trial. <i>BMJ Open</i> , 2014, 4, e004227.	1.9	15
158	Adherence to Guidelines for Glucose Assessment in Starting Second-Generation Antipsychotics. <i>Pediatrics</i> , 2014, 134, e1308-e1314.	2.1	36
159	Common use of high doses of antipsychotic medications in older Asian patients with schizophrenia (2001-2009). <i>International Journal of Geriatric Psychiatry</i> , 2014, 29, 359-366.	2.7	19
160	The prevalence and moderators of clinical pain in people with schizophrenia: A systematic review and large scale meta-analysis. <i>Schizophrenia Research</i> , 2014, 160, 1-8.	2.0	70
161	National Trends in the Mental Health Care of Children, Adolescents, and Adults by Office-Based Physicians. <i>JAMA Psychiatry</i> , 2014, 71, 81.	11.0	368
162	Quetiapine versus aripiprazole in children and adolescents with psychosis - protocol for the randomised, blinded clinical Tolerability and Efficacy of Antipsychotics (TEA) trial. <i>BMC Psychiatry</i> , 2014, 14, 199.	2.6	10

#	ARTICLE	IF	CITATIONS
163	Cardiometabolic Risk in Patients With First-Episode Schizophrenia Spectrum Disorders. <i>JAMA Psychiatry</i> , 2014, 71, 1350.	11.0	318
164	Elevated Blood Urea Nitrogen and Medical Outcome of Psychiatric Inpatients. <i>Psychiatric Quarterly</i> , 2014, 85, 111-120.	2.1	1
165	Second-Generation Antipsychotic Use in Children and Adolescents: A Six-Month Prospective Cohort Study in Drug-Naïve Patients. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , 2014, 53, 1179-1190.e4.	0.5	76
166	Markers of inflammation in schizophrenia: association vs. causation. <i>World Psychiatry</i> , 2014, 13, 189-192.	10.4	54
167	Emerging drugs for schizophrenia: an update. <i>Expert Opinion on Emerging Drugs</i> , 2014, 19, 511-531.	2.4	44
168	SENTIA: a systematic online monitoring registry for children and adolescents treated with antipsychotics. <i>SpringerPlus</i> , 2014, 3, 187.	1.2	10
169	BDNF Val66Met polymorphism and antipsychotic-induced tardive dyskinesia occurrence and severity: A meta-analysis. <i>Schizophrenia Research</i> , 2014, 152, 365-372.	2.0	20
170	Risk of Diabetes in Children and Adolescents Exposed to Antipsychotics: A Nationwide 12-Year Case-Control Study. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , 2014, 53, 971-979.e6.	0.5	22
171	Sudden unexpected death in schizophrenia: Autopsy findings in psychiatric inpatients. <i>Schizophrenia Research</i> , 2014, 155, 72-76.	2.0	68
172	Type and duration of subsyndromal symptoms in youth with bipolar I disorder prior to their first manic episode. <i>Bipolar Disorders</i> , 2014, 16, 478-492.	1.9	91
173	Prevalence and correlates of antipsychotic polypharmacy in children and adolescents receiving antipsychotic treatment. <i>International Journal of Neuropsychopharmacology</i> , 2014, 17, 1095-1105.	2.1	45
174	Diabetes Risk Potentially Underestimated in Youth and Children Receiving Antipsychotics. <i>JAMA Psychiatry</i> , 2014, 71, 209.	11.0	17
175	National Trends in Second-Generation Antipsychotic Augmentation for Nonpsychotic Depression. <i>Journal of Clinical Psychiatry</i> , 2014, 75, 490-497.	2.2	34
176	Body Mass Index Identified as an Independent Predictor of Psychiatric Readmission. <i>Journal of Clinical Psychiatry</i> , 2014, 75, e573-e577.	2.2	37
177	Pharmacoeconomics of Antipsychotic Use in Youth with ADHD: Trends and Clinical Implications. <i>Current Psychiatry Reports</i> , 2013, 15, 382.	4.5	35
178	Improving metabolic parameters of antipsychotic child treatment (IMPACT) study: rationale, design, and methods. <i>Child and Adolescent Psychiatry and Mental Health</i> , 2013, 7, 31.	2.5	19
179	Antipsychotic polypharmacy: A Japanese survey of prescribers' attitudes and rationales. <i>Psychiatry Research</i> , 2013, 209, 406-411.	3.3	28
180	Early Antipsychotic Response to Aripiprazole in Adolescents With Schizophrenia: Predictive Value for Clinical Outcomes. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , 2013, 52, 689-698.e3.	0.5	23

#	ARTICLE	IF	CITATIONS
181	Aripiprazole for the treatment of pediatric bipolar I disorder: a 30-week, randomized, placebo-controlled study. <i>Bipolar Disorders</i> , 2013, 15, 138-149.	1.9	62
182	Prevalence of the metabolic syndrome in patients with borderline personality disorder: results from a cross-sectional study. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2013, 263, 205-213.	3.2	60
183	Associations Among Obesity, Acute Weight Gain, and Response to Treatment with Olanzapine in Adolescent Schizophrenia. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2013, 23, 522-530.	1.3	35
184	Adjunctive Use of Nonsteroidal Anti-inflammatory Drugs for Schizophrenia: A Meta-analytic Investigation of Randomized Controlled Trials. <i>Schizophrenia Bulletin</i> , 2013, 39, 1230-1241.	4.3	168
185	Response to Bartoli et al.. <i>American Journal of Psychiatry</i> , 2013, 170, 928-929.	7.2	2
186	Efficacy and safety of individual second-generation vs. first-generation antipsychotics in first-episode psychosis: a systematic review and meta-analysis. <i>International Journal of Neuropsychopharmacology</i> , 2013, 16, 1205-1218.	2.1	257
187	Prediction of Functional Outcome in Individuals at Clinical High Risk for Psychosis. <i>JAMA Psychiatry</i> , 2013, 70, 1133.	11.0	202
188	Antipsychotic Polypharmacy in a Treatment-Refractory Schizophrenia Population Receiving Adjunctive Treatment With Electroconvulsive Therapy. <i>Journal of ECT</i> , 2013, 29, 271-276.	0.6	17
189	CNR1 Gene and Risk of the Metabolic Syndrome in Patients With Schizophrenia. <i>Journal of Clinical Psychopharmacology</i> , 2013, 33, 186-192.	1.4	30
190	Treatment of adolescents with early-onset schizophrenia spectrum disorders. <i>Current Opinion in Psychiatry</i> , 2013, 26, 219-230.	6.3	82
191	A meta-analysis of cardio-metabolic abnormalities in drug naïve, first-episode and multi-episode patients with schizophrenia versus general population controls. <i>World Psychiatry</i> , 2013, 12, 240-250.	10.4	220
192	Non-adherence to medication in patients with psychotic disorders: epidemiology, contributing factors and management strategies. <i>World Psychiatry</i> , 2013, 12, 216-226.	10.4	356
193	Metabolic Syndrome and Metabolic Abnormalities in Bipolar Disorder: A Meta-Analysis of Prevalence Rates and Moderators. <i>American Journal of Psychiatry</i> , 2013, 170, 265-274.	7.2	336
194	Prescribing of psychotropic medications to children and adolescents: <i>quo vadis</i> ?. <i>World Psychiatry</i> , 2013, 12, 127-128.	10.4	9
195	Early Nonresponse Determined by the Clinical Global Impressions Scale Predicts Poorer Outcomes in Youth with Schizophrenia Spectrum Disorders Naturalistically Treated with Second-Generation Antipsychotics. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2013, 23, 665-675.	1.3	30
196	Termination of Clozapine Treatment Due to Medical Reasons. <i>Journal of Clinical Psychiatry</i> , 2013, 74, 603-613.	2.2	193
197	Pediatric Schizophrenia. , 2013, , 1-6.		0
198	The Field of Schizophrenia: Strengths, Weaknesses, Opportunities, and Threats. <i>Schizophrenia Bulletin</i> , 2012, 38, 1-4.	4.3	6

#	ARTICLE	IF	CITATIONS
199	Osteoporosis and fracture risk in people with schizophrenia. <i>Current Opinion in Psychiatry</i> , 2012, 25, 415-429.	6.3	91
200	Effectiveness of a Cognitive Behavioral Weight Management Intervention in Obese Patients With Psychotic Disorders Compared to Patients With Nonpsychotic Disorders or No Psychiatric Disorders. <i>Journal of Clinical Psychopharmacology</i> , 2012, 32, 458-464.	1.4	14
201	Differences in Body Mass Index (BMI)-Scores and Weight Status in a Dutch Pediatric Psychiatric Population With and Without Use of Second-Generation Antipsychotics. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2012, 22, 166-173.	1.3	18
202	Metabolic and cardiovascular adverse effects associated with antipsychotic drugs. <i>Nature Reviews Endocrinology</i> , 2012, 8, 114-126.	9.6	832
203	Association Between Common Variants Near the Melanocortin 4 Receptor Gene and Severe Antipsychotic Drug-Induced Weight Gain. <i>Archives of General Psychiatry</i> , 2012, 69, 904.	12.3	165
204	Body Weight and Metabolic Adverse Effects of Aripiprazole, Lurasidone, Lurasidone and Paliperidone in the Treatment of Schizophrenia and Bipolar Disorder. <i>CNS Drugs</i> , 2012, 26, 733-759.	5.9	136
205	Safety and tolerability of antipsychotic polypharmacy. <i>Expert Opinion on Drug Safety</i> , 2012, 11, 527-542.	2.4	163
206	When can patients with potentially life-threatening adverse effects be rechallenged with clozapine? A systematic review of the published literature. <i>Schizophrenia Research</i> , 2012, 134, 180-186.	2.0	129
207	Acute and maintenance effects of non-pharmacologic interventions for antipsychotic associated weight gain and metabolic abnormalities: A meta-analytic comparison of randomized controlled trials. <i>Schizophrenia Research</i> , 2012, 140, 159-168.	2.0	161
208	Prevalence and correlates of antipsychotic polypharmacy: A systematic review and meta-regression of global and regional trends from the 1970s to 2009. <i>Schizophrenia Research</i> , 2012, 138, 18-28.	2.0	255
209	Antipsychotic Polypharmacy. <i>Psychiatric Clinics of North America</i> , 2012, 35, 661-681.	1.3	93
210	Recent advances in understanding and mitigating adipogenic and metabolic effects of antipsychotic drugs. <i>Frontiers in Psychiatry</i> , 2012, 3, 62.	2.6	25
211	Are Antipsychotics or Antidepressants Needed for Psychotic Depression?. <i>Journal of Clinical Psychiatry</i> , 2012, 73, 486-496.	2.2	109
212	Treatment of Maladaptive Aggression in Youth: CERT Guidelines II. Treatments and Ongoing Management. <i>Pediatrics</i> , 2012, 129, e1577-e1586.	2.1	117
213	Antipsychotic Drug Administration Does Not Correlate with Prolonged Rate-Corrected QT Interval in Children and Adolescents: Results from a Nested Case-Control Study. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2011, 21, 365-368.	1.3	28
214	Weight Gain and Metabolic Risks Associated with Antipsychotic Medications in Children and Adolescents. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2011, 21, 517-535.	1.3	221
215	Antipsychotic polypharmacy: A survey study of prescriber attitudes, knowledge and behavior. <i>Schizophrenia Research</i> , 2011, 131, 58-62.	2.0	78
216	Physical illness in patients with severe mental disorders. II. Barriers to care, monitoring and treatment guidelines, plus recommendations at the system and individual level. <i>World Psychiatry</i> , 2011, 10, 138-151.	10.4	631

#	ARTICLE	IF	CITATIONS
217	Antipsychotic drugs and obesity. <i>Trends in Molecular Medicine</i> , 2011, 17, 97-107.	6.7	256
218	Efficacy and safety of second-generation antipsychotics in children and adolescents with psychotic and bipolar spectrum disorders: Comprehensive review of prospective head-to-head and placebo-controlled comparisons. <i>European Neuropsychopharmacology</i> , 2011, 21, 621-645.	0.7	168
219	Incidence of Tardive Dyskinesia with Risperidone or Olanzapine in the Elderly: Results from a 2-Year, Prospective Study in Antipsychotic-Naïve Patients. <i>Neuropsychopharmacology</i> , 2011, 36, 1738-1746.	5.4	45
220	Quantifying Clinical Relevance in the Treatment of Schizophrenia. <i>Clinical Therapeutics</i> , 2011, 33, B16-B39.	2.5	94
221	Obesity and coronary risk in patients treated with second-generation antipsychotics. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2011, 261, 417-423.	3.2	29
222	Physical illness in patients with severe mental disorders. I. Prevalence, impact of medications and disparities in health care. <i>World Psychiatry</i> , 2011, 10, 52-77.	10.4	1,767
223	Randomized controlled trials in schizophrenia: opportunities, limitations, and trial design alternatives. <i>Dialogues in Clinical Neuroscience</i> , 2011, 13, 155-172.	3.7	38
224	Determinants of Poor Dental Care in Patients With Schizophrenia. <i>Journal of Clinical Psychiatry</i> , 2011, 72, 140-143.	2.2	52
225	Switching and Combining Antipsychotics. <i>CNS Spectrums</i> , 2010, 15, 8-11.	1.2	7
226	Research in people with psychosis risk syndrome: a review of the current evidence and future directions. <i>Journal of Child Psychology and Psychiatry and Allied Disciplines</i> , 2010, 51, 390-431.	5.2	167
227	Antipsychotic and mood stabilizer efficacy and tolerability in pediatric and adult patients with bipolar I mania: a comparative analysis of acute, randomized, placebo-controlled trials. <i>Bipolar Disorders</i> , 2010, 12, 116-141.	1.9	181
228	Past and Present Progress in the Pharmacologic Treatment of Schizophrenia. <i>Journal of Clinical Psychiatry</i> , 2010, 71, 1115-1124.	2.2	188
229	Antipsychotics Associated with the Development of Type 2 Diabetes in Antipsychotic-Naïve Schizophrenia Patients. <i>Neuropsychopharmacology</i> , 2010, 35, 1997-2004.	5.4	183
230	Do antipsychotic medications reduce or increase mortality in schizophrenia? A critical appraisal of the FIN-11 study. <i>Schizophrenia Research</i> , 2010, 117, 68-74.	2.0	99
231	Management of antipsychotic-related weight gain. <i>Expert Review of Neurotherapeutics</i> , 2010, 10, 1175-1200.	2.8	95
232	Pharmacologic treatment of schizophrenia. <i>Dialogues in Clinical Neuroscience</i> , 2010, 12, 345-357.	3.7	86
233	Antipsychotic Combinations vs Monotherapy in Schizophrenia: A Meta-analysis of Randomized Controlled Trials. <i>Schizophrenia Bulletin</i> , 2009, 35, 443-457.	4.3	360
234	Cardiometabolic Risk of Second-Generation Antipsychotic Medications During First-Time Use in Children and Adolescents. <i>JAMA - Journal of the American Medical Association</i> , 2009, 302, 1765.	7.4	867

#	ARTICLE	IF	CITATIONS
235	Second-Generation Antipsychotic-associated Diabetes Mellitus and Diabetic Ketoacidosis: Mechanisms, Predictors, and Screening Need. <i>Journal of Clinical Psychiatry</i> , 2009, 70, 765-766.	2.2	35
236	Equally increased risk for metabolic syndrome in patients with bipolar disorder and schizophrenia treated with second-generation antipsychotics. <i>Bipolar Disorders</i> , 2008, 10, 788-797.	1.9	143
237	Monitoring and management of antipsychotic-related metabolic and endocrine adverse events in pediatric patients. <i>International Review of Psychiatry</i> , 2008, 20, 195-201.	2.8	78
238	Predictors of Remission, Schizophrenia, and Bipolar Disorder in Adolescents with Brief Psychotic Disorder or Psychotic Disorder Not Otherwise Specified Considered At Very High Risk for Schizophrenia. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2008, 18, 475-490.	1.3	50
239	Antipsychotic Use in Children and Adolescents: Minimizing Adverse Effects to Maximize Outcomes. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , 2008, 47, 9-20.	0.5	274
240	Side Effects of Second-Generation Antipsychotics: The Experiences, Views and Monitoring Practices of Australian Child Psychiatrists. <i>Australasian Psychiatry</i> , 2008, 16, 253-262.	0.7	39
241	Antipsychotic Use in Children and Adolescents: Minimizing Adverse Effects to Maximize Outcomes. <i>Focus (American Psychiatric Publishing)</i> , 2008, 6, 368-378.	0.8	6
242	Tardive dyskinesia and new antipsychotics. <i>Current Opinion in Psychiatry</i> , 2008, 21, 151-156.	6.3	331
243	Assessing and maximizing the safety and tolerability of antipsychotics used in the treatment of children and adolescents. <i>Journal of Clinical Psychiatry</i> , 2008, 69 Suppl 4, 26-36.	2.2	45
244	Differentiation in the Preonset Phases of Schizophrenia and Mood Disorders: Evidence in Support of a Bipolar Mania Prodrome. <i>Schizophrenia Bulletin</i> , 2007, 33, 703-714.	4.3	175
245	One-Year Incidence Rates of Tardive Dyskinesia in Children and Adolescents Treated with Second-Generation Antipsychotics: A Systematic Review. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2007, 17, 647-655.	1.3	87
246	Acute and Long-Term Adverse Effects of Antipsychotics. <i>CNS Spectrums</i> , 2007, 12, 10-14.	1.2	29
247	Balancing Efficacy and Safety in Treatment with Antipsychotics. <i>CNS Spectrums</i> , 2007, 12, 12-20.	1.2	64
248	Pharmacological Management of Bipolar Disorder in a Youth With Diabetes. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , 2007, 46, 1375-1379.	0.5	3
249	Does antipsychotic polypharmacy increase the risk for metabolic syndrome?. <i>Schizophrenia Research</i> , 2007, 89, 91-100.	2.0	219
250	First-Episode Psychosis: A Window of Opportunity for Best Practices. <i>CNS Spectrums</i> , 2007, 12, 1-16.	1.2	18
251	Recognizing and Monitoring Adverse Events of Second-Generation Antipsychotics in Children and Adolescents. <i>Child and Adolescent Psychiatric Clinics of North America</i> , 2006, 15, 177-206.	1.9	163
252	Endocrine and Metabolic Adverse Effects of Psychotropic Medications in Children and Adolescents. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , 2006, 45, 771-791.	0.5	343

#	ARTICLE	IF	CITATIONS
253	Metabolic Syndrome and the Risk of Coronary Heart Disease in 367 Patients Treated With Second-Generation Antipsychotic Drugs. <i>Journal of Clinical Psychiatry</i> , 2006, 67, 575-583.	2.2	175
254	Prospective Study of Adolescents with Subsyndromal Psychosis: Characteristics and Outcome. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2005, 15, 418-433.	1.3	35
255	Cost-Effective Screening for the Metabolic Syndrome in Patients Treated With Second-Generation Antipsychotic Medications. <i>American Journal of Psychiatry</i> , 2005, 162, 1217-1221.	7.2	89
256	Lower Risk for Tardive Dyskinesia Associated With Second-Generation Antipsychotics: A Systematic Review of 1-Year Studies. <i>American Journal of Psychiatry</i> , 2004, 161, 414-425.	7.2	653
257	Pharmacogenetics of antipsychotic-induced weight gain. <i>Psychopharmacology</i> , 2004, 174, 477-89.	3.1	83
258	Early Prediction of Antipsychotic Response in Schizophrenia. <i>American Journal of Psychiatry</i> , 2003, 160, 2063-2065.	7.2	159
259	The Schizophrenia Prodrome Revisited: A Neurodevelopmental Perspective. <i>Schizophrenia Bulletin</i> , 2003, 29, 633-651.	4.3	327
260	The Assessment of "Prodromal Schizophrenia": Unresolved Issues and Future Directions. <i>Schizophrenia Bulletin</i> , 2003, 29, 717-728.	4.3	67
261	Treatment Models and Designs for Intervention Research During the Psychotic Prodrome. <i>Schizophrenia Bulletin</i> , 2003, 29, 747-756.	4.3	17